Treatment pause

OTHER2 trials

Sponsors

University Hospital, Bordeaux, Jinling Hospital, China

Conditions

Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC ScoreMetastatic Clear Cell Renal Cell CarcinomaMetastatic Renal Cell Carcinoma

Phase 2

CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk

RecruitingNCT07615348

Jinling Hospital, ChinaMetastatic Clear Cell Renal Cell Carcinoma

Start: 2026-06-16End: 2029-08-10Target: 75Updated: 2026-08-11

Phase 3

Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors

Active, not recruitingNCT05219318

University Hospital, BordeauxGood or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score, Metastatic Renal Cell Carcinoma

Start: 2023-01-23End: 2027-01-31Updated: 2025-06-04

Related Papers

Strategic treatment pause of first-line immune checkpoint inhibitor + VEGFR-tyrosine kinase inhibitor in patients with good or intermediate risk metastatic renal cell carcinoma (mRCC) in response at 1 year of treatment (SPICI-GETUG R05): A non-inferiority randomized clinical trial.

Journal of Clinical Oncology2024-01-29